Misery of thrush could be over within four years after vaccine trial success
An injection could be developed to treat the uncomfortable infection by 2020
Scientists are currently conducting studies to develop a vaccine which would be a simple treatment for thrush.
According to The Times, clinical trials of the injection have shown “strong results”.
Millions of people in Britain suffer from the yeast infection every year.
Selinda Orr, a researcher at Cardiff University who investigates the immune responses of fungal infections has said that this vaccine could soon be on hand to help many women.
In a talk at the British Science Festival in Swansea, she explained the vaccines that could soon be available.
Related stories
NovaDigm Therapeutics, an American biotechnology company, is currently developing the NDV-3 vaccine, which is a form of one of the proteins found on the surface of the fungus that is responsible for causing the condition.
The human trial of the vaccination, which involves 188 patients, has shown the injection to be safe and has positive implications for its future.
It is thought this could be the first powerful drug to prevent patients contracting chronic thrush.
Thrush is a type of yeast infection that can affect both men and women although it is much more common among women with half of the female population suffering from it at some point between adolescence and menopause.
It can affect the mouth, vagina and sometimes the penis.
Current treatments include oral tablets and creams to sooth uncomfortable symptoms.